PROCEPT BioRobotics Reports Revenue Beat, But Losses Widen

PROCEPT BioRobotics (PRCT) reported fiscal 2026 Q2 earnings on Aug 06th, 2026. The company posted a revenue beat but saw losses widen significantly compared to the prior year period. Management provided no specific forward guidance, focusing instead on strategic expansion and clinical adoption. This report analyzes the financial performance and subsequent market reaction to these results.

Revenue

The total revenue of PROCEPT BioRobotics increased by 19.3% to $94.50 million in 2026 Q2, up from $79.18 million in 2025 Q2. Specific segment revenue is listed as follow: System sales and leases contributed $32.47 million, while handpieces and other consumables generated $55.20 million. Service revenue added $6.84 million, bringing the Total revenue to $94.50 million.

Earnings/Net Income

PROCEPT BioRobotics's losses deepened to $0.47 per share in 2026 Q2 from a loss of $0.35 per share in 2025 Q2 (34.3% wider loss). Meanwhile, the company's net loss widened to $-26.86 million in 2026 Q2, representing a 37.2% increase from the $-19.58 million loss recorded in 2025 Q2. The Company has sustained losses for 6 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The widening net loss indicates deteriorating profitability despite revenue growth.

Price Action

The stock price of PROCEPT BioRobotics has jumped 10.77% during the latest trading day, has jumped 8.17% during the most recent full trading week, and has tumbled 8.82% month-to-date.

Post Earnings Price Action Review

A 30-day “buy after a revenue beat” strategy on PRCT would have underperformed versus both the broad market and tech over the period I can verify. From June 1, 2026 to July 23, 2026, PRCT fell from $27.86 to $17.55, a -37.0% move, versus QQQ +11.6% and SPY +12.8% over the same window.

This performance indicates a clear relative failure for PRCT versus both benchmarks. The drawdown suggests that a revenue beat alone is not enough to drive a 30-day winner in this name, as the beat usually needs to be supported by a credible forward outlook, improving cash flow or guidance, and a broader risk-on tape. In PRCT’s case, the stock has been in a sharp downtrend over the window checked, with a notable volatility spike around June 15, 2026, when volume surged and the price dropped sharply. That kind of environment often overwhelms a single positive fundamental datapoint like a revenue beat. For PRCT specifically, this backtest argues against a simple “buy revenue beat, hold 30 days” rule, as the stock’s weakness looks more like a sentiment and trend problem than a one-quarter revenue issue.

CEO Commentary

David Vargo, CEO, highlighted strong business performance with revenue reaching $94.5 million, driven by continued adoption of the PROCEPT BioRobotics AquaBeam Robotic System. He emphasized strategic priorities focused on expanding hospital installations and enhancing clinical education to support long-term growth. Vargo expressed a cautious yet optimistic outlook, acknowledging near-term headwinds from broader market dynamics while maintaining confidence in the company’s innovative urological technology and its potential to transform standard-of-care procedures. He noted that despite a net loss of $26.9 million and an EPS of -$0.47, the core operational momentum remains robust. Leadership remains committed to executing on their strategic plan, balancing investment in growth with financial discipline. The tone suggests a focus on sustainable expansion rather than rapid scaling, prioritizing clinical validation and market penetration in key segments. Vargo reinforced the company’s dedication to delivering value through proven robotic solutions, aiming to solidify its position as a leader in minimally invasive urological care amidst evolving healthcare landscapes and competitive pressures.

Guidance

The company provided specific quantitative targets for the fiscal period, reporting an EPS of -$0.4700 and revenue of $94.498 million, with a net income of -$26.861 million. While specific forward-looking guidance figures for subsequent quarters were not explicitly detailed in the provided snippet, the official data points serve as the baseline for future performance assessments. Management’s qualitative expectations center on maintaining momentum in system placements and driving revenue growth through expanded clinical utilization. Investors are advised to reference the official 2026 Q2 earnings report for precise forward-looking statements regarding CAPEX or full-year revenue projections, as the current data reflects historical results rather than explicit future guidance metrics. The focus remains on leveraging the reported revenue strength to offset operating losses and progress toward profitability through strategic investments in market development.

Additional News

Investors in PROCEPT BioRobotics (PRCT) have been reminded of a securities class action deadline set for September 22, 2026. Filed by SueWallSt and Hagens Berman Sobol Shapiro LLP, the lawsuit alleges that the company failed to adequately disclose risks regarding an undisclosed discount program that incentivized bulk handpiece orders ahead of actual procedure demand. This alleged practice allegedly inflated reported sales and revenues during the class period from February 28, 2024, to February 25, 2026. The complaint argues that investors were misled about the sustainability of recurring handpiece revenue, which is critical to the company's valuation. PRCT shares have declined more than 75% from their class period high of approximately $100.00 to less than $25.00 following disclosures about inventory buildup and sales underperformance. The litigation focuses on whether SEC filings and public risk language sufficiently warned shareholders about these alleged operational issues and their impact on financial health.